TECregen AG

Based in Basel, Switzerland, and founded in 2024 by Georg Hollander, Filippo Oliveri, and Ignacio Moraga, TECregen AG, focuses on creating advanced therapies to enhance immune function. In January 2026, TECregen AG raised CHF 10 million in seed funding led by Boehringer Ingelheim Venture, with participation from LifeSpan Vision Ventures, CARMA FUND Management, Eos BioInnovation, High-Tech Gruenderfonds, JFG Life Sciences Foundation, and Zurich Cantonal Bank. As of January 2026, Klaas P. Zuideveld is the Chief Executive Officer (CEO) of the company.

TECregen specializes in the development and commercialization of innovative thymopoietic therapies aimed at regenerating the thymus and restoring immune balance. Their core product offerings focus on precision-engineered biologics that leverage advanced ligand engineering, targeted delivery systems, and functional screening, resulting in tailored therapeutics designed to combat immune decline, cancer, and inflammatory diseases. The company's solutions are intended for healthcare providers and research institutions engaged in immunology and regenerative medicine, particularly targeting populations affected by compromised immune systems. TECregen’s products have been introduced to various international markets, aiming to serve patients and healthcare practitioners in North America, Europe, and Asia, addressing a growing demand for effective immune restoration therapies.

TECregen's revenue model is primarily structured around partnerships with healthcare providers and research institutions, emphasizing B2B transactions. The company engages in collaborations that facilitate the delivery of its regenerative therapies, incorporating contractual agreements that outline the terms for product supply and distribution. Specific pricing plans for TECregen's offerings have not been disclosed; however, the company establishes pricing based on the unique characteristics of its flagship thymopoietic products and the needs of healthcare clients. Revenue generation is anticipated through direct sales to healthcare facilities and potential licensing agreements with pharmaceutical companies aiming to integrate TECregen's technologies into broader therapeutic applications.

The company plans to use the January 2026 funding to advance development of thymopoietic biologics that rejuvenate thymic epithelial cells and restore immune function.